Does central sleep apnea (CSA) carry the same cardiovascular risk as obstructive sleep apnea (OSA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Central Sleep Apnea Carries Higher Cardiovascular Risk Than Obstructive Sleep Apnea

Central sleep apnea (CSA) is associated with significantly worse cardiovascular outcomes and mortality compared to obstructive sleep apnea (OSA), with CSA patients demonstrating 1.5-3 fold higher mortality risk even after adjusting for comorbidities.

Key Differences in Cardiovascular Risk

Mortality and Survival Outcomes

  • CSA demonstrates substantially higher mortality rates: In a large Veterans Health Administration cohort of nearly 1.5 million patients, CSA was associated with an adjusted hazard ratio of 1.53 for mortality compared to OSA, with 25.1% of CSA patients dying during the study period versus 14.9% of OSA patients 1

  • CSA predicts incident atrial fibrillation more strongly: In the Sleep Heart Health Study, CSA was associated with 2-3 fold increased odds of developing atrial fibrillation (OR 2.00-3.00), while OSA showed no significant association with incident AF 2

  • Nearly one-fifth of CSA patients die within 5 years of diagnosis, highlighting the severe prognostic implications 1

Pathophysiologic Distinctions

CSA represents a marker of underlying cardiac dysfunction rather than a primary disorder: CSA is generally considered a consequence of heart failure and central nervous system or cardiac dysfunction, whereas OSA is an independent risk factor that can cause cardiovascular disease 3, 4

  • OSA is independently associated with increased risk for cardiovascular disease including hypertension, coronary artery disease, stroke, atrial fibrillation, and congestive heart failure through mechanisms of upper airway obstruction and intermittent hypoxemia 3

  • CSA correlates with severity of hemodynamic impairment and when present, is associated with increased arrhythmic risk and higher cardiac mortality 4

Specific Cardiovascular Associations

For OSA:

  • Perioperative cardiovascular risk: OSA patients undergoing noncardiac surgery have 2.5-fold greater risk of postoperative pulmonary complications and increased incidence of MI and AF 3

  • Stroke risk: Among patients with ischemic stroke or TIA, OSA affects approximately 38-40% of patients and is associated with increased risk for functional impairment and stroke recurrence 3

For CSA:

  • Heart failure association: The presence of heart failure dramatically increases mortality in CSA patients (HR 7.4) compared to OSA patients with heart failure (HR 4.3) 1

  • Strongest predictors of CSA mortality include heart failure, history of cerebrovascular disease, hemiplegia, male sex, and being underweight 1

  • Prior myocardial infarction and atrial fibrillation are the comorbidities most strongly associated with CSA, with adjusted odds ratios of 1.88 and 1.85 respectively 5

Treatment Implications and Outcomes

Critical Treatment Consideration for CSA:

Adaptive servo-ventilation (ASV) in heart failure with reduced ejection fraction is contraindicated: The SERVE-HF trial demonstrated increased all-cause and cardiovascular mortality with ASV treatment in this population, with greater risk of sudden death 3

  • Persistent CSA despite optimal medical therapy indicates worse prognosis: Patients with persistent CSA at 3 months despite CPAP and optimal medical therapy had greater mortality 3

  • Paradoxically, greater amounts of CSA-Cheyne-Stokes breathing at randomization were associated with better survival, suggesting CSA may represent a compensatory mechanism in heart failure 3

OSA Treatment Benefits:

  • CPAP effectively reduces cardiovascular risk in OSA: Treatment improves blood pressure (particularly nocturnal measurements), reduces AHI, improves sleepiness, and may reduce stroke risk with good adherence 3

  • Blood pressure reduction is clinically significant in hypertensive and resistant hypertensive OSA patients treated with PAP 3

Clinical Bottom Line

CSA represents a fundamentally different and more ominous cardiovascular risk profile than OSA. While OSA is an independent, treatable risk factor for cardiovascular disease, CSA typically reflects advanced underlying cardiac pathology with substantially higher mortality risk. The 2-3 fold increased mortality and atrial fibrillation risk in CSA patients, combined with the potential harm from certain treatments (ASV in heart failure), underscores that these are distinct entities requiring different clinical approaches and prognostic counseling 2, 1, 4.

References

3
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What are the recommended treatment options for obstructive sleep apnea syndrome?
How should obstructive sleep apnea be managed?
A 41-year-old woman with a history of sleep talking presents with nocturnal episodes of waking several times per week for three months, finding raw meat in her bed, without recollection of eating and feeling half awake and half asleep; polysomnography shows an apnea‑hypopnea index of 3.4 events per hour and somnambulism. What is the next best step in management?
In a patient with undiagnosed and untreated obstructive sleep apnea who has a Holter monitor showing a 3.3‑second sinus pause at 8 PM, is it reasonable to attribute the pause to the sleep apnea?
What is the American Academy of Sleep Medicine (AASM) stance on Expiratory Positive Airway Pressure (EPAP) devices, such as EXCITE, for the treatment of Obstructive Sleep Apnea (OSA)?
What are the contraindications for constructing an orthotopic neobladder after radical cystectomy?
What are the clinical indications for terbinafine?
Can magnesium supplementation be used to improve sleep in otherwise healthy adults with occasional insomnia, and what is the appropriate dose and contraindications?
Which muscle relaxant is safe for a patient with a history of syncope and atrial fibrillation?
What is the recommended management for a patient who develops a new right bundle‑branch block with left posterior fascicular block on ECG during an acute inferior wall myocardial infarction?
How should insulin therapy be selected for a 62‑year‑old man with uncontrolled type 2 diabetes and an infected ankle ulcer when he is admitted (a) to a private hospital with no budget constraints, and (b) to a government hospital with limited resources?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question